Genenta Science Provides Update on CEO Ownership

Core Viewpoint - Genenta Science provides an update on the ownership position of its CEO and Co-Founder, Pierluigi Paracchi, highlighting his significant investment in the company through open-market purchases of American Depositary Shares (ADSs) [1][2]. Company Ownership - Pierluigi Paracchi has acquired a total of 30,000 ADSs through open-market purchases, with no reported sales [2]. - As of December 19, 2025, Mr. Paracchi owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta's outstanding share capital [3]. Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing hematopoietic stem cell therapies for solid tumor cancers [4]. - The company's lead product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing immune responses [4]. - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients, indicating potential for reprogramming the tumor microenvironment and inducing T cell responses [4]. - A Phase 1/2a study for metastatic Renal Cell Carcinoma has been initiated, which will explore combinations with immune checkpoint inhibitors [4]. - Genenta's therapies are designed as one-time monotherapies but may also enhance the efficacy of other approved treatments when used in combination [4].